WO2003080545A3 - Substituted phenylacetic acids - Google Patents

Substituted phenylacetic acids Download PDF

Info

Publication number
WO2003080545A3
WO2003080545A3 PCT/US2003/008899 US0308899W WO03080545A3 WO 2003080545 A3 WO2003080545 A3 WO 2003080545A3 US 0308899 W US0308899 W US 0308899W WO 03080545 A3 WO03080545 A3 WO 03080545A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenylacetic acids
substituted phenylacetic
substituted
acids
phenylethanols
Prior art date
Application number
PCT/US2003/008899
Other languages
French (fr)
Other versions
WO2003080545A2 (en
Inventor
Zuchun Zhao
Xin Chen
Jianchao Wang
Hongbin Sun
Jack Shih-Chieh Liang
Original Assignee
Metabolex Inc
Zuchun Zhao
Xin Chen
Jianchao Wang
Hongbin Sun
Jack Shih-Chieh Liang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc, Zuchun Zhao, Xin Chen, Jianchao Wang, Hongbin Sun, Jack Shih-Chieh Liang filed Critical Metabolex Inc
Priority to KR10-2004-7014829A priority Critical patent/KR20050008661A/en
Priority to BR0308537-6A priority patent/BR0308537A/en
Priority to NZ535603A priority patent/NZ535603A/en
Priority to AU2003237787A priority patent/AU2003237787B2/en
Priority to CA002479338A priority patent/CA2479338A1/en
Priority to MXPA04009040A priority patent/MXPA04009040A/en
Priority to EP03736445A priority patent/EP1487843A4/en
Priority to JP2003578306A priority patent/JP2005520858A/en
Publication of WO2003080545A2 publication Critical patent/WO2003080545A2/en
Publication of WO2003080545A3 publication Critical patent/WO2003080545A3/en
Priority to NO20044436A priority patent/NO20044436L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C07D249/20—Benzotriazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Substituted phenylacetic acids, phenylethanols and related compounds are provided that are useful in treating or controlling a number of diseases associated with glucose metabolism, lipid metabolism and insulin secretion.
PCT/US2003/008899 2002-03-20 2003-03-19 Substituted phenylacetic acids WO2003080545A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR10-2004-7014829A KR20050008661A (en) 2002-03-20 2003-03-19 Substituted phenylacetic acids
BR0308537-6A BR0308537A (en) 2002-03-20 2003-03-19 Compound, composition, and methods for treating type 2 diabetes and hyperuricemia, modulating insulin resistance and alleviating hyperlipidemia in an individual and prodrug agent
NZ535603A NZ535603A (en) 2002-03-20 2003-03-19 Substituted phenylacetic acids
AU2003237787A AU2003237787B2 (en) 2002-03-20 2003-03-19 Substituted phenylacetic acids
CA002479338A CA2479338A1 (en) 2002-03-20 2003-03-19 Substituted phenylacetic acids
MXPA04009040A MXPA04009040A (en) 2002-03-20 2003-03-19 Substituted phenylacetic acids.
EP03736445A EP1487843A4 (en) 2002-03-20 2003-03-19 Substituted phenylacetic acids
JP2003578306A JP2005520858A (en) 2002-03-20 2003-03-19 Substituted phenylacetic acid
NO20044436A NO20044436L (en) 2002-03-20 2004-10-19 Substituted phenylacetic acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36696102P 2002-03-20 2002-03-20
US60/366,961 2002-03-20

Publications (2)

Publication Number Publication Date
WO2003080545A2 WO2003080545A2 (en) 2003-10-02
WO2003080545A3 true WO2003080545A3 (en) 2004-01-22

Family

ID=28454828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/008899 WO2003080545A2 (en) 2002-03-20 2003-03-19 Substituted phenylacetic acids

Country Status (13)

Country Link
US (2) US7078421B2 (en)
EP (1) EP1487843A4 (en)
JP (1) JP2005520858A (en)
KR (1) KR20050008661A (en)
CN (2) CN100338073C (en)
AU (1) AU2003237787B2 (en)
BR (1) BR0308537A (en)
CA (1) CA2479338A1 (en)
MX (1) MXPA04009040A (en)
NO (1) NO20044436L (en)
NZ (1) NZ535603A (en)
WO (1) WO2003080545A2 (en)
ZA (1) ZA200407802B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE405840T1 (en) 2002-12-19 2008-09-15 Scripps Research Inst COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING
SE0301009D0 (en) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (en) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (en) 2003-08-21 2009-11-10 استرازينيكا ايه بي Substiuted phenoxacetic as pharmaceutced compunds for treating respiratory diseases such as asthma and copd
NZ547696A (en) 2003-12-23 2009-12-24 Astex Therapeutics Ltd Pyrazole derivatives as protein kinase modulators
CN1922143A (en) * 2004-02-18 2007-02-28 麦它波莱克斯股份有限公司 Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents
EP1768968A1 (en) * 2004-05-20 2007-04-04 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
US7622491B2 (en) * 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
KR101251622B1 (en) * 2004-09-24 2013-04-08 가부시키가이샤 한도오따이 에네루기 켄큐쇼 Light emitting device
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
EP1817282B1 (en) 2004-11-23 2011-07-20 AstraZeneca AB Phenoxyacetic acid derivatives useful for treating respiratory diseases
WO2006102375A2 (en) 2005-03-21 2006-09-28 Metabolex, Inc. Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
EP1933832A2 (en) 2005-06-23 2008-06-25 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CN101316853B (en) * 2005-08-04 2014-09-24 西特里斯药业公司 Oxazolopyridine derivatives as SIRTUIN modulators
WO2007019417A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
EP1948630A2 (en) * 2005-11-05 2008-07-30 AstraZeneca AB Novel compounds
JP2009519308A (en) * 2005-12-15 2009-05-14 アストラゼネカ・アクチエボラーグ Substituted diphenyl ethers, amines, sulfides and methane for the treatment of respiratory diseases
EP2074223A4 (en) * 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
CN103265501B (en) * 2007-03-27 2015-06-03 盐野义制药株式会社 Method for producing N-phenyl-N'-phenylsulfonylpiperazine derivative
CN102015606B (en) 2007-06-08 2015-02-04 满康德股份有限公司 IRE-1a inhibitors
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
UA100983C2 (en) * 2007-07-05 2013-02-25 Астразенека Аб Biphenyloxypropanoic acid as crth2 modulator and intermediates
AU2008340182A1 (en) * 2007-12-21 2009-07-02 The University Of Sydney Translocator protein ligands
EA021424B1 (en) 2008-12-19 2015-06-30 Сертрис Фармасьютикалз, Инк. Thiazolopyridine sirtuin modulating compounds
WO2012035039A1 (en) 2010-09-15 2012-03-22 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
SG191040A1 (en) 2010-12-23 2013-08-30 Pfizer Glucagon receptor modulators
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
KR101395146B1 (en) * 2011-02-09 2014-05-16 부산대학교 산학협력단 New compounds having skin whitening, antioxidant and PPAR activity, and medical use thereof
EP2734503B1 (en) 2011-07-22 2015-09-16 Pfizer Inc. Quinolinyl glucagon receptor modulators
CA2847293C (en) 2011-09-16 2017-03-28 Richard Frederic Labaudiniere Solid forms of a transthyretin dissociation inhibitor
CN108329330B (en) * 2017-01-20 2021-05-04 复旦大学 2-benzyloxy phenyl oxazolopyridine compound and pharmaceutical application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0077938A2 (en) * 1981-10-23 1983-05-04 Mitsubishi Kasei Corporation N-(3-substituted aminophenyl) tetrahydrophthalimides and herbicidal composition
JPS60109578A (en) * 1983-11-17 1985-06-15 Mitsubishi Chem Ind Ltd 3-(substituted phenyl)-5-substituted-1,3,4-oxazolin-2-one compound and herbicide containing said compound as active component
US5476946A (en) * 1993-02-09 1995-12-19 Bayer Aktiengesellschaft 1-aryltriazolin(ethi)ones
US6506747B1 (en) * 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072585A (en) * 1960-01-13 1963-01-08 American Cyanamid Co Vinylbenzyloxy phenylbenzotriazoles
FR1451171A (en) * 1961-04-21 1966-01-07 Jacques Logeais Soc D Expl Des Etherified and esterified derivatives of 2-o-hydroxyphenyl-oxadiazole-1, 3, 4 and process for their preparation
US3444299A (en) 1964-02-07 1969-05-13 American Cyanamid Co Methods for the control and prevention of helminths with phenylbenzothiazolium compounds
GB1097053A (en) 1964-03-16 1967-12-29 Dow Chemical Co Substituted benzothiazolium compounds and complexes thereof for use in animal husbandry
US3558778A (en) 1966-10-27 1971-01-26 Dow Chemical Co Methods and compositions for use in animal husbandry
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
BE754245A (en) 1969-08-01 1970-12-31 Sumitomo Chemical Co PHENOXY CARBOXYLIC ACID DERIVATIVES
FR2082478A5 (en) * 1970-03-17 1971-12-10 Thomson Csf
GB1341222A (en) * 1970-04-17 1973-12-19 Takeda Chemical Industries Ltd Oxadiazole derivatives
DE2358789A1 (en) * 1973-02-07 1975-06-05 Merck Patent Gmbh HYDRATROPASIC ACID DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
US4053626A (en) * 1973-03-13 1977-10-11 Merck Patent Gesellschaft Mit Beschrankter Haftung Cholesterol level-lowering phenoxyacetic acids
IL44356A (en) * 1973-03-13 1977-10-31 Merck Patent Gmbh Phenoxyacetic acid derivatives and processes for their preparation
US3876791A (en) 1973-11-30 1975-04-08 Uniroyal Inc Control of acarids using certain benzothiazoles or benzothiazolines
DE2415867A1 (en) * 1974-04-02 1975-10-09 Merck Patent Gmbh PHENOXY ALCANOL DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
US3894057A (en) * 1974-05-28 1975-07-08 Hoechst Co American Tetrahydrobenzofuranylphenoxycarboxylic acids, esters
US4001268A (en) 1974-08-07 1977-01-04 The United States Of America As Represented By The Secretary Of The Air Force Substituted phenyl-benzimidazo compounds
JPS6039072B2 (en) 1976-07-28 1985-09-04 藤沢薬品工業株式会社 N-substituted phenylamino fatty acid derivatives
JPS5371071A (en) 1976-12-08 1978-06-24 Teijin Ltd Alpha-phenoxyacetic acid derivs.
SE8003277L (en) 1979-05-04 1980-11-05 Continental Pharma BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND USE, AND COMPOSITIONS CONTAINING THESE DERIVATIVES
US4508882A (en) 1981-08-24 1985-04-02 Asahi Glass Company Ltd. Benzotriazole compound and homopolymer or copolymers thereof
DE3236730A1 (en) 1982-10-04 1984-04-05 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING BENZOXAZOLYL AND BENZTHIAZOLYLOXYPHENOXYPROPION ACID DERIVATIVES
US4528311A (en) 1983-07-11 1985-07-09 Iolab Corporation Ultraviolet absorbing polymers comprising 2-hydroxy-5-acrylyloxyphenyl-2H-benzotriazoles
JPS6140270A (en) * 1984-08-01 1986-02-26 Morishita Seiyaku Kk Pyridazinone derivative
JPS6140266A (en) * 1984-08-01 1986-02-26 Morishita Seiyaku Kk Pyrazole derivative
US4714762A (en) 1986-10-31 1987-12-22 Warner-Lambert Company Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
JPH0670025B2 (en) 1987-08-07 1994-09-07 鐘紡株式会社 Benzothiazole derivative and antirheumatic agent containing the compound as an active ingredient
GB8720365D0 (en) 1987-08-28 1987-10-07 Sandoz Ltd Organic compounds
US4863802A (en) 1987-12-31 1989-09-05 General Electric Company UV-stabilized coatings
JPH01305069A (en) 1988-05-31 1989-12-08 Shionogi & Co Ltd Benzotriazole derivative and fluorescent light emitting reagent containing the same derivative
CA2034309C (en) 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
US5281571A (en) * 1990-10-18 1994-01-25 Monsanto Company Herbicidal benzoxazinone- and benzothiazinone-substituted pyrazoles
US5278314A (en) 1991-02-12 1994-01-11 Ciba-Geigy Corporation 5-thio-substituted benzotriazole UV-absorbers
ATE189217T1 (en) * 1993-03-19 2000-02-15 Merck & Co Inc PHENOXYPHENYLACETIC ACID DERIVATIVES
US5874431A (en) 1993-08-28 1999-02-23 Cancer Research Campaign Technology Limited Benzazole compounds
EP0774965A4 (en) * 1994-08-08 1997-10-29 Merck & Co Inc Phenoxyphenylacetic acid derivatives
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5455152A (en) 1994-09-27 1995-10-03 Eastman Kodak Company Benzotriazole based UV absorbing monomers and photographic elements containing polymers formed from them
US5700819A (en) 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
GB9503946D0 (en) 1995-02-28 1995-04-19 Cancer Res Campaign Tech Benzazole compounds
US5500332A (en) 1995-04-26 1996-03-19 Eastman Kodak Company Benzotriazole based UV absorbers and photographic elements containing them
US5766834A (en) 1996-05-17 1998-06-16 Eastman Kodak Company Photographic element containing ultraviolet absorbing polymer
EP0927167A1 (en) 1996-08-14 1999-07-07 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
EP0839808A1 (en) * 1996-10-29 1998-05-06 Novartis AG Pyrazole derivatives, processes for their preparation, and their use as herbicides
JP2001505566A (en) 1996-11-22 2001-04-24 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド Use of selected benzotriazole derivatives to protect human and animal skin and hair from the harmful effects of UV irradiation
JP3714574B2 (en) 1997-03-26 2005-11-09 ダイセル化学工業株式会社 Ultraviolet absorber, method for producing the same and synthetic resin composition
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
JP3271991B2 (en) 1997-11-07 2002-04-08 大鵬薬品工業株式会社 Benzimidazole derivatives and pharmaceutically acceptable salts thereof
WO1999058521A1 (en) * 1998-05-12 1999-11-18 American Home Products Corporation 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia
US6013659A (en) 1998-09-04 2000-01-11 University Of Pittsburgh Methods of reducing tumor colony number using novel benzothiazole compounds
BR9916363A (en) 1998-12-18 2001-12-11 Axys Pharm Inc Compound, pharmaceutical composition and method to treat or prevent a thromboembolic disorder
AU763356C (en) 1999-12-27 2004-08-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
DE10014645A1 (en) * 2000-03-24 2001-09-27 Merck Patent Gmbh New amidino-aryl substituted biphenyl derivatives and analogs as Factor Xa inhibitors, are useful for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy or angina pectoris
CA2479069A1 (en) * 2002-03-18 2003-09-25 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Hetero-bridge substituted 8-arylquinoline pde4 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0077938A2 (en) * 1981-10-23 1983-05-04 Mitsubishi Kasei Corporation N-(3-substituted aminophenyl) tetrahydrophthalimides and herbicidal composition
JPS60109578A (en) * 1983-11-17 1985-06-15 Mitsubishi Chem Ind Ltd 3-(substituted phenyl)-5-substituted-1,3,4-oxazolin-2-one compound and herbicide containing said compound as active component
US5476946A (en) * 1993-02-09 1995-12-19 Bayer Aktiengesellschaft 1-aryltriazolin(ethi)ones
US6506747B1 (en) * 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1487843A4 *

Also Published As

Publication number Publication date
US20060264630A1 (en) 2006-11-23
MXPA04009040A (en) 2005-01-25
EP1487843A2 (en) 2004-12-22
NZ535603A (en) 2007-10-26
CN1653073A (en) 2005-08-10
CN100338073C (en) 2007-09-19
AU2003237787A1 (en) 2003-10-08
BR0308537A (en) 2005-02-09
US7078421B2 (en) 2006-07-18
EP1487843A4 (en) 2010-03-10
US7642358B2 (en) 2010-01-05
KR20050008661A (en) 2005-01-21
CN101172983A (en) 2008-05-07
NO20044436L (en) 2004-12-06
US20040029933A1 (en) 2004-02-12
ZA200407802B (en) 2006-11-29
WO2003080545A2 (en) 2003-10-02
CA2479338A1 (en) 2003-10-02
JP2005520858A (en) 2005-07-14
AU2003237787B2 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
WO2003080545A3 (en) Substituted phenylacetic acids
AU2003273612A1 (en) Percutaneously introduced blood pump and related methods
AU2003259537A1 (en) Blood glucose level control
AU2003234529A1 (en) Glp-1 gene delivery for the treatment of type 2 diabetes
AU2003211376A1 (en) Drug administration method
AU2003225160A1 (en) "biosensor for dialysis therapy"
AU2002349630A1 (en) Medical treatment system and production method therefor
WO2004050115A3 (en) Combination treatment using exendin-4 and thiazolidinediones
AU2003251933A1 (en) Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
AU2003257162A1 (en) Catheter for cardiac injection
EP1634605A3 (en) treatment of dyslipidemia in a patient having type 2 diabetes
AU2003252182A1 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
AU2003232044A1 (en) Composition and method for dermatological treatment
AUPS160602A0 (en) Therapeutic method
AU2003236521A1 (en) Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
AU2002309083A1 (en) Method for identifying drugs for the treatment of type ii diabetes
WO2006049657A3 (en) Insulin secretion by anthocyanins and anthocyanidins
AU2003244082A1 (en) Drug composition for blood sugar control
AU2003215624A1 (en) An optically acitve pyridine derivative and a medicament containing the same
AU2003211288A1 (en) Sub-package, medicine sub-package continuous strip, and method of producing medicine sub-package continuous strip
AU2003268706A1 (en) PROCESS FOR PRODUCING OPTICALLY ACTIVE Alpha-SUBSTITUTED CYSTEINE OR SALT THEREOF, INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING THE SAME
AU2003276071A1 (en) Decomposition-resistant polyamide and method for the production thereof
AU2003299652A1 (en) Methods for treating diabetes
AU2003298215A1 (en) Method for obtaining a biologically active blood serum treated with electroshock and the utilization thereof
AU2003214171A1 (en) Method for treating diabetic ulcers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2479338

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003578306

Country of ref document: JP

Ref document number: PA/A/2004/009040

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047014829

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003736445

Country of ref document: EP

Ref document number: 535603

Country of ref document: NZ

Ref document number: 200407802

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003237787

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3020/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 20038110393

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003736445

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047014829

Country of ref document: KR